ClearPoint Neuro, Inc. (CLPT) News
Filter CLPT News Items
CLPT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CLPT News From Around the Web
Below are the latest news stories about CLEARPOINT NEURO INC that investors may wish to consider to help them evaluate CLPT as an investment opportunity.
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the BrainOnly Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global therapy-enabling platform ... |
The ClearPoint Neuro, Inc. (NASDAQ:CLPT) Third-Quarter Results Are Out And Analysts Have Published New ForecastsLast week, you might have seen that ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) released its third-quarter result to the... |
ClearPoint Neuro Reports Third Quarter 2024 ResultsAchieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company ... |
Those who invested in ClearPoint Neuro (NASDAQ:CLPT) five years ago are up 213%The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you... |
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast Today SOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and ... |
ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company’s 2024 third quarter on Thursday, November 7th at 4:30 p.m |
ClearPoint Neuro Announces Early Repayment of $10 Million NoteSOLANA BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that on August 23, 2024, it provided for the full early repayment of the principal amount and interest on a $10 million convertible note held by PTC Therapeutics Inc., which would have matured in January 2025 according to its terms. The convertible note was issued |
ClearPoint Neuro Reports Second Quarter 2024 ResultsSecond Quarter Revenue Growth +32%; Record Revenue AchievedSOLANA BEACH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June 30, 2024. Second Quarter Highlights Reported quarterly revenue of $7.9 million, a 32% year-over-year increase;Product revenue across all segments more than doubl |
ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 second quarter on Wednesday, August 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company’s 2024 second quarter on Wednesday, August 7th at 4:30 p.m |
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical TrialParkinson’s Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients’ Own Autologous Replacement NeuronsSOLANA BEACH, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner Aspen Neuroscience, Inc. on use of the ClearPoint Neuro Navigation System to transplant dopaminergic neuron pr |